ResMed Inc. vs ZIM Integrated Shipping Services Ltd — how do they compare? ResMed Inc. trades at $194.34 (market cap $28.81B), while ZIM Integrated Shipping Services Ltd trades at $24.99 (market cap $2.93B). The key difference: ResMed Inc. is far larger — about 9.8× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| RMD | ZIM | |
|---|---|---|
Market Cap | $28.81B | $2.93B |
Sector | Health | Industrials |
52-Week High | $293.73 | $29.27 |
52-Week Low | $182.82 | $12.44 |
Enterprise Value | $27.99B | $6.78B |
Dividend Yield | 1.21% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
ZIM trades at $24.31, showing minimal daily movement. The stock faces a bearish technical outlook with mixed earnings, including a Q1 2026 miss. Financially, it maintains a strong cash position and low valuation multiples, but profitability has declined from 2025 to 2026. Recent news is dominated by merger uncertainty with Hapag-Lloyd and leadership changes.
The outlook is cautious due to regulatory risks around the merger and volatile shipping rates. Upside exists if the deal proceeds or freight markets tighten, but downside risk is significant if the merger fails, with analyst targets near $16.75. High cash burn and insider selling add to near-term pressure.
Trailing returns across standard periods
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →